# An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee Replacement

> **NCT00859313** · PHASE2 · COMPLETED · sponsor: **Talphera, Inc** · enrollment: 30 (actual)

## Conditions studied

- Pain, Postoperative

## Interventions

- **DRUG:** Sufentanil NanoTab PCA System/15 mcg

## Key facts

- **NCT ID:** NCT00859313
- **Lead sponsor:** Talphera, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2012-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00859313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00859313, "An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee Replacement". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00859313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*